<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7277397\results\search\testTrace\results.xml">
  <result pre="young piglets. Similarly, porcine hemagglutinating encephalomyelitis virus (PHEV) causes enteric" exact="infection" post="in pigs but can also lead to encephalitis by"/>
  <result pre="chicken industry [7]. In domestic cats, a mild or asymptomatic" exact="infection" post="has been associated with feline enteric coronavirus (FCoV) [10],"/>
  <result pre="and MERS in severity and has recently led to extreme" exact="quarantine" post="measures including sealing off large cities, closing borders and"/>
  <result pre="there are no antiviral drugs or vaccines available for the" exact="treatment" post="of COVID-19 [41]. The urgent need for treatment has"/>
  <result pre="for the treatment of COVID-19 [41]. The urgent need for" exact="treatment" post="has therefore triggered a variety of approaches to design"/>
  <result pre="and protection. Typically, three general methods are employed for antiviral" exact="treatment" post="of coronaviruses [80]: (i) application of existing broad-spectrum antiviral"/>
  <result pre="coronaviruses [80]: (i) application of existing broad-spectrum antiviral drugs; (ii)" exact="screening" post="of chemical libraries containing many existing compounds or databases;"/>
  <result pre="as a combination therapy with other antiretroviral agents for the" exact="treatment" post="of HIV-1 infections has provided durable virologic suppression and"/>
  <result pre="durable virologic suppression and improved immunological outcomes [84]. Lopinavir/ritonavir combination" exact="treatment" post="was evaluated in marmosets with a MERS-like disease [85]."/>
  <result pre="MERS-like disease [85]. In comparison to mycophenolate mofetil (MFF), the" exact="treatment" post="showed improved clinical, radiological and pathological outcomes and lower"/>
  <result pre="time to clinical improvement was one day shorter for lopinavir/ritonavir" exact="treatment" post="and although gastrointestinal adverse events were more common, serious"/>
  <result pre="events were less frequent. Overall, the study indicated that the" exact="treatment" post="offered no benefit compared to standard care. Another approach"/>
  <result pre="administered together with interferon-Î±2a in adult patients with laboratory-confirmed MERS-CoV" exact="infection" post="and pneumonia needing ventilation support [92]. The study demonstrated"/>
  <result pre="rate at 14 days but not at 28 days of" exact="treatment" post="compared to the control group of patients. The adenosine"/>
  <result pre="be susceptible to SARS-CoV-2 [96]. The first case of compassionate" exact="treatment" post="of COVID-19 with intravenous administration of remdesivir took place"/>
  <result pre="has been approved in Russia and China for prevention and" exact="treatment" post="of influenza [100]. Antiviral effect against Zika virus (ZIKV),"/>
  <result pre="MERS-CoV Antiviral activity, but not against SARS-CoV [90] FIP Successful" exact="treatment" post="of FIP [91] Ribavirin MERS-CoV Improved survival at 14"/>
  <result pre="auto-immune disease drug chloroquine on coronaviruses [96]. Chloroquine blocks virus" exact="infection" post="and interferes with the glycosylation of cellular receptors of"/>
  <result pre="Despite the small sample size, the study indicated that hydroxychloroquine" exact="treatment" post="was associated with a significant viral load reduction and"/>
  <result pre="the fight against coronaviruses. In this context, case studies of" exact="treatment" post="with the Shuanghuanglian oral liquid (SHL) of a family"/>
  <result pre="with high fever diagnosed with COVID-19 was confined into an" exact="isolation" post="ward five days later, where she started to take"/>
  <result pre="and diarrhea. Two days after she was confined in an" exact="isolation" post="ward, she started to take SHL three times a"/>
  <result pre="severe pneumonia also showed improvement. Another potential approach for COVID-19" exact="treatment" post="relates to AHCC, an Î±-glucan-based standardized mushroom extract from"/>
  <result pre="capsules have proven to be efficient for the prevention and" exact="treatment" post="of respiratory infections caused by influenza A [114] but"/>
  <result pre="1 (ATR1) blockers such as losartan, commonly used for the" exact="treatment" post="of hypertension [108], for a reduction in aggressiveness and"/>
  <result pre="inhibition and will be useful for the development of antigen" exact="detection" post="tests and serological assays. Moreover, it adds to the"/>
  <result pre="into fetal rhesus kidney FRhK4 cells before or after SARS-CoV" exact="infection" post="and the inhibitory effects were verified by the decrease"/>
  <result pre="and viral titers. Four siRNAs demonstrated potent inhibition of SARS-CoV" exact="infection" post="and replication. Prophylactic effects with up to 90% inhibition"/>
  <result pre="in Vero cells [122]. It was further demonstrated that SARS-CoV" exact="infection" post="was reduced in ACE2-silenced cell lines, providing an attractive"/>
  <result pre="with the SARS-CoV spike protein during the entry stage of" exact="infection" post="[123]. In the context of MERS-CoV the ORF1ab region"/>
  <result pre="encoding the replicase polyproteins plays a vital role in viral" exact="infection" post="and therefore represents a suitable target for disease control."/>
  <result pre="silencing of nine different MERS-CoV strains for exploration of the" exact="treatment" post="of MERS-CoV at the genomic level [124]. In attempts"/>
  <result pre="silico approaches, two multi-epitope vaccines against MERS-CoV were designed by" exact="screening" post="CTL and HTL epitopes from 13 different MERS-CoV proteins"/>
  <result pre="or other related coronaviruses [57]. In a study on SARS-CoV," exact="screening" post="of experimentally determined B and T cell-derived epitopes from"/>
  <result pre="with infectious TCoV and clinical signs were monitored by an" exact="immunofluorescence" post="antibody assay. Immunized turkeys showed less clinical signs and"/>
  <result pre="enhanced viral replication [161]. In the context of COVID-19, prior" exact="infection" post="with other coronaviruses, from common cold to SARS-CoV, may"/>
  <result pre="plasma has previously been used successfully as post-exposure prophylaxis and/or" exact="treatment" post="of SARS and MERS [166]. In the context of"/>
  <result pre="were weak, but high titers of IgG were obtained. The" exact="treatment" post="allowed the patient to be released from mechanical ventilation"/>
  <result pre="do not permit an evaluation of the efficacy of the" exact="treatment" post="and further larger clinical trials are required. 4. Conclusions"/>
  <result pre="for 5 days and 11 days after 10 days of" exact="treatment" post="compoared to 15 days for the control group and"/>
  <result pre="of intravenous remdesivir will be compared to standard of care" exact="treatment" post="of COVID-19 patients with the first results expected by"/>
  <result pre="100 patients demonstrated superiority of chloroquine phosphate compared to control" exact="treatment" post="in inhibition of pneumonia exacerbation [173]. Moreover, in a"/>
  <result pre="PCR detection, pyrexia, cough or lung CT findings between the" exact="treatment" post="and control groups. However, in the lopinavir/ritonavir group, 38.1%"/>
  <result pre="although drugs developed for other infectious diseases might provide alternative" exact="treatment" post="strategies for COVID-19 when evaluated in well-designed and well-executed"/>
  <result pre="HaanC.A.RottierP.J.Molecular interactions in the assembly of coronavirusesAdv. Virus Res.20056416523016139595 80.LuH.Drug" exact="treatment" post="options for the 2019-new coronavirus (2019.nCoV)Biosci. Trends.202010.5582/bst.2020.01020 81.KruseR.L.Therapeutic strategies"/>
  <result pre="with Severe Covid-19N. Engl. J. Med.202010.1056/NEJMoa2001282 88.PrujisssersA.J.DenisonM.R.Nucleoside analogues for the" exact="treatment" post="of coronavirus infectionsCurr. Opin. Virol.201935576210.1016/j.coviro.2019.04.00231125806 89.ChuC.K.GadthulaS.ChenX.ChooH.OlgenS.BarnardD.L.SidwellR.W.Antiviral activity of nucleoside"/>
  <result pre="peritonitis (FIP) virus in tissue culture and in experimental cat" exact="infection" post="studiesVet. Microbiol.201821922623310.1016/j.vetmic.2018.04.02629778200 92.OmraniA.S.SaadM.M.BaigK.BahloulA.Abdul-MatinM.AlaidaroosA.Y.AlmakhlafiG.A.AlbarrakM.M.MemishZ.A.AlbarrakA.M.Ribavirin and interferon alpha-2a for severe Middle"/>
  <result pre="retrospective cohort studyJ. Infect.202010.1016/j.jinf.2020.03.002 103.GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraE.V.et al.Hydroxychloroquine and azothromycin as a" exact="treatment" post="of COVID-19: Results of an open-label non-randomized clinical trialInt."/>
  <result pre="SARS-CoV infectionbioRxiv2020preprint10.1101/2020.03.11.987958 110.VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.SeidahG.S.NicholS.T.Chlkoroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol. J.200526910.1186/1743-422X-2-6916115318 111.ColsonP.RolainJ.-M.RaoultD.Chloroquine for the 2019 novel coronavirus"/>
  <result pre="A recommendation to examine the effect of hydrochloroquine in preventing" exact="infection" post="and progressionJ. Antimicrob. Chemother.202011410.1093/jac/dkaa114 113.Di PierroF.BertuccioliA.CavecchiaI.Possible therapeutic role of"/>
  <result pre="the functional roles of host cell proteins involved in coronavirus" exact="infection" post="using highly specific and scalable RNA interference (RNAi) approachMethods"/>
  <result pre="den BrandJ.M.RajV.S.VolzA.WohlseinP.SmitsS.L.SchipperD.BestebroerT.M.OkbaN.FuxR.et al.An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV" exact="infection" post="in dromedary camelsScience2016351778110.1126/science.aad128326678878 152.VeitS.JanyS.FuxR.SutterG.VolzA.CD8+ T Cells Responding to the"/>
  <result pre="166.BlochE.M.ShohamS.CasadevallA.SachaisB.S.ShazB.WintersJ.L.van BurskirkC.GrossmanB.J.JoynerM.HendersonJ.P.et al.Deployment of convalescent plasma for the prevention and" exact="treatment" post="of COVID-19J. Clin. Investig.202013874510.1172/JCI13874532254064 167.ZhangL.PangR.XueX.BaoJ.YeS.DajY.ZhengY.FuQ.HuZ.YiY.Anti-SARS-CoV-2 virus antibody levels in"/>
  <result pre="in COVID-19BMJ2020369m143210.1136/bmj.m143232269046 173.GaoJ.TianZ.YangX.Breakthrough: Chloroquine phosphate has shown apparent efficacy in" exact="treatment" post="of COVID-19 associated pneumonia in clinical studiesBiosci. Trends202014727310.5582/bst.2020.0104732074550 174.ChenZ.HuJ.ZhangZ.JiangS.HanS.YanD.ZhuangR.HuB.ZhangZ.Efficacy"/>
  <result pre="to hydroxychloroquineGut19943556957010.1136/gut.35.4.5698175002 178.ChorinE.DaiM.ShulmanE.WadhwaniL.Bar-CohenR.BarbhayiaC.AizerA.HolmesD.BernsteinS.SpinelliM.et al.The QT interval in patients with SARS-CoV-2" exact="infection" post="treated with hydroxychloroquine/azithromycinmedRxiv202010.1101/2020.04.02.20047050v1 179.LiY.XieZ.LinW.CaiW.WenC.GuanY.MoX.WangJ.WangY.PengP.et al.An exploratory randomized, controlled study"/>
  <result pre="PEDV Gastroenteritis in pigs High morbidity, mortality [4] PHEV Enteric" exact="infection" post="Diarrhea, encephalitis [5] BCoV Respiratory tract infection Significant loss"/>
  <result pre="[4] PHEV Enteric infection Diarrhea, encephalitis [5] BCoV Respiratory tract" exact="infection" post="Significant loss in cattle industry [6,7] RCoV Respiratory tract"/>
  <result pre="infection Significant loss in cattle industry [6,7] RCoV Respiratory tract" exact="infection" post="Model system [8] IBV Respiratory infections, renal disease Significant"/>
  <result pre="Significant losses in the chicken industry [7,9] FCoV Respiratory tract" exact="infection" post="Mild or asymptomatic [10] FIPV Infectious peritonitis Lethal FIP"/>
  <result pre="SW1 found in deceased whale [13] Bat CoV Respiratory tract" exact="infection" post="Potential threat of epidemics [14] SHC014-CoV Risk of epidemic"/>
  <result pre="Chronic demyelination Mouse model for MS [17] Î± HCoV-229E Respiratory" exact="infection" post="15%â€&quot;30% of annual common cold [18] Î± HCoV-NL63 Respiratory"/>
  <result pre="infection 15%â€&quot;30% of annual common cold [18] Î± HCoV-NL63 Respiratory" exact="infection" post="Also associated with croup [18,19] Î² HcoV-OC43 Respiratory infection"/>
  <result pre="Respiratory infection Also associated with croup [18,19] Î² HcoV-OC43 Respiratory" exact="infection" post="15%â€&quot;30% of annual common cold [20] Î² HcoV-HKU1 Respiratory"/>
  <result pre="infection 15%â€&quot;30% of annual common cold [20] Î² HcoV-HKU1 Respiratory" exact="infection" post="15%â€&quot;30% of annual common cold [20] SARS-CoV SARS Epidemic"/>
  <result pre="SARS-CoV Suppression of SARS symptoms in primates [121] SARS-CoV Reduced" exact="infection" post="in ACE2-silenced cells [122] siRNAs, miRNAs SARS-CoV Knockdown of"/>
 </snippets>
</snippetsTree>
